PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
1.44%
Net income growth under 50% of CRWV's 7.67%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
32.41%
D&A growth well above CRWV's 26.15%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-127.78%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-127.78%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
-33.87%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-57.27%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
-103.13%
Negative yoy purchasing while CRWV stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
-1601.12%
We reduce yoy other investing while CRWV is 202.79%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-371.47%
Both yoy lines negative, with CRWV at -70.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-20.08%
Negative yoy issuance while CRWV is 4.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
93.28%
Buyback growth of 93.28% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.